{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:11:09Z","timestamp":1785247869629,"version":"3.55.0"},"reference-count":15,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"DOI":"10.1182\/bloodadvances.2025019563","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:58:18Z","timestamp":1775505498000},"page":"4907-4911","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Cytomegalovirus reactivation in patients with multiple myeloma receiving bispecific antibodies"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6217-6501","authenticated-orcid":false,"given":"Enric","family":"Sastre-Escol\u00e0","sequence":"first","affiliation":[{"name":"1Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, University of Barcelona, L\u2019Hospitalet de Llobregat, Spain"},{"name":"2Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"3Hospital Duran i Reynals, Institut Catal\u00e0 d'Oncologia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma K.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"4National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"5Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"6Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"7Department of Infectious Diseases and Immunology, Austin Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8692-4145","authenticated-orcid":false,"given":"Michelle K.","family":"Yong","sequence":"additional","affiliation":[{"name":"4National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"5Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"6Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"8Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3334-8263","authenticated-orcid":false,"given":"Violet","family":"Zhu","sequence":"additional","affiliation":[{"name":"4National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"5Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"6Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"4National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"6Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"9Department of Clinical Hematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-5373","authenticated-orcid":false,"given":"Amit S.","family":"Khot","sequence":"additional","affiliation":[{"name":"6Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"9Department of Clinical Hematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[{"name":"4National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"5Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"6Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"8Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0213-5470","authenticated-orcid":false,"given":"Benjamin W.","family":"Teh","sequence":"additional","affiliation":[{"name":"4National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"5Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"6Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"4","key":"2026072809373659700_bib1","doi-asserted-by":"crossref","first-page":"e14083","DOI":"10.1111\/tid.14083","article-title":"Epidemiology, treatment patterns, and disease burden of cytomegalovirus in hematopoietic cell transplant recipients in selected countries outside of Europe and North America: a systematic review","volume":"25","author":"Cho","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"2026072809373659700_bib2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/imj.15496","article-title":"Cytomegalovirus DNAemia and disease: current-era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation","volume":"52","author":"Tay","year":"2022","journal-title":"Intern Med J"},{"issue":"3","key":"2026072809373659700_bib3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2026072809373659700_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ejh.12551","article-title":"Cytomegalovirus reactivation in patients with multiple myeloma","volume":"96","author":"Hasegawa","year":"2016","journal-title":"Eur J Haematol"},{"issue":"14","key":"2026072809373659700_bib5","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","article-title":"Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026072809373659700_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026072809373659700_bib7","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.blre.2025.101339","article-title":"Management of relapsed refractory multiple myeloma: evidence-based guide to community oncologists","volume":"74","author":"Mushtaq","year":"2025","journal-title":"Blood Rev"},{"issue":"3","key":"2026072809373659700_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica"},{"issue":"19","key":"2026072809373659700_bib9","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026072809373659700_bib10","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026072809373659700_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026072809373659700_bib12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2026072809373659700_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026072809373659700_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/v17010133","article-title":"Herpesvirus infections after chimeric antigen receptor T-cell therapy and bispecific antibodies: a review","volume":"17","author":"Sassine","year":"2025","journal-title":"Viruses"},{"issue":"8","key":"2026072809373659700_bib15","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/4907\/2533272\/blooda_adv-2025-019563-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/4907\/2533272\/blooda_adv-2025-019563-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:37:42Z","timestamp":1785245862000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/14\/4907\/567595\/Cytomegalovirus-reactivation-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":15,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019563","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,28]]},"published":{"date-parts":[[2026,7,15]]}}}